Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK mRNA multivalent influenza vaccine in adults
NCT06431607Phase 2Completed
- Sponsor
- GSK
- Start
- May 2024
- Primary completion
- Dec 2024
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of GSK4382276A in influenza, sponsored by GSK. Primary endpoint: Geometric Mean Titer at 29 days. Started May 2024; status: completed.
02
Drugs
GSK4382276A
03
Conditions
influenza
Beyond the preview
Go deeper on NCT06431607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06431607.